COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

Genfit
Genfit is trying to ensure its studies can hit the ground running when the pandemic subsides. (Genfit)

Genfit has told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis (NASH) data. The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.

France’s Genfit disclosed the need to wait on FDA feedback before taking a look at the phase 3 data last month, triggering a drop in its stock price. At that time, Genfit said it was delaying the unblinding “to incorporate the latest FDA insights expected by the end of March.” With March now almost over, Genfit has provided an update on the situation.

In the latest update, Genfit said that it does not “currently anticipate that the COVID-19 situation will significantly delay receipt of this feedback.” FierceBiotech is awaiting clarification from Genfit, but the comment, and timing of its release, suggests the feedback will be later than originally expected.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

How much later has implications for Genfit’s efforts to bring elafibranor to market in NASH. Genfit thinks the results from the 1,000 or so patients in the locked database will support FDA approval, but that will remain uncertain until the feedback is shared and the data are unblinded and analyzed. 

Intercept Pharmaceuticals, the one company Genfit is trailing in the NASH race, has also faced some COVID-19 disruption, with the FDA delaying an advisory committee meeting to discuss its filing from April to June. Intercept has a PDUFA action date of June 26. 

While Genfit thinks COVID-19 is unlikely to significantly set back the unblinding of its data, other parts of its operation face more disruption. Genfit has paused all phase 1 trials of elafibranor. The studies “are necessary to support the elafibranor NDA submission for NASH,” Genfit said. Genfit has also paused enrollment in a phase 2 liver fat study and put the initiation of a phase 2 NASH combination trial and a phase 3 primary biliary cholangitis (PBC) program on hold.

In the face of the disruption, Genfit is trying to ensure its studies can hit the ground running when the pandemic subsides. Work toward the phase 2 combination trial and phase 3 PBC study is ongoing, and “all supporting activities pertaining to continuation of ongoing studies or the initiation of new studies will continue.”

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.